What is Cosmetovigilance?
Essentially, Cosmetovigilance is the continuous compilation, evaluation and monitoring of cosmetic products’ safety, concerning human health. Manufacturers have the responsibility to determine that cosmetic products and their ingredients are safe before they enter the market, as well as to gather reports of adverse reactions.

Market surveillance is essential to determine the success of the marketing of a cosmetic product. Serious undesirable effects need to be reported to the competent authority and transmitted to the competent authorities of the other EU Member States.  

Cosmetovigilance is the post-market surveillance of the cosmetic products which are available in the market for consumers. This post-market surveillance is the way to keep record of adverse reactions that may occur with the use of the cosmetic product and additionally perform and follow-up corrective actions when needed. Cosmetovigilance also allows to control or rule out potentially hazardous ingredients that may be present in cosmetic products 

In the European Union (EU), cosmetovigilance is established under the Cosmetics Regulation (EC) No. 1223/2009. As stated in this Regulation, “ensuring traceability of a cosmetic product throughout the whole supply chain helps to make market surveillance simpler and more efficient”.  

Member States need to monitor compliance with the cosmetics Regulation via in-market controls of the cosmetic products available on the market. 

According to the EU Cosmetics Regulation (EC) No. 1223/2009, a Product Information File (PIF) for each cosmetic product must be prepared by a safety assessor (qualified person) before the product is placed on the market. This PIF shall be made readily accessible to the competent authority of the Member State (at one single address within the Community).  

An undesirable effect is an ‘adverse reaction for human health attributable to the normal or reasonably foreseeable use of a cosmetic product’. A serious undesirable effect means ‘an undesirable effect which results in temporary or permanent functional incapacity, disability, hospitalisation, congenital anomalies or an immediate vital risk or death’. 

The Responsible Person, distributors, end users or health professionals can report serious undesirable effects to the competent authority of the EU Member State, which shall immediately transmit the information to the competent authorities of the other Member States (and to the Responsible Person, if it was not reported by it). All serious undesirable effects (known and reasonably expected), the name of the cosmetic product (specific identification) and corrective measures taken (if any), need to be included in the information reported. Competent authorities may use the information for purposes of in-market surveillance, market analysis, evaluation and consumer information and can likewise request from the responsible person a list of cosmetic products that contain the substances which have raised serious doubts in terms of safety.  

The Responsible Person and/or authorities have the responsibility to implement the corrective or preventive measures necessary. A change in the instructions of use or warnings of the label are examples of these measures. 

References: 

  1. Vigan M, Castelain F. Cosmetovigilance: Definition, Regulation and Use “In Practice”. Eur J Dermatol. 2014;24(6):643-649.
  2. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009, on cosmetic products 

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »